Physical exercise for late-life major depression. 2015

M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
Martino Belvederi Murri, MD, Section of Psychiatry, Department of Neuroscience, Ophthalmology, Genetics and Infant-Maternal Science, University of Genoa, Genoa, Italy, and Department of Psychological Medicine, Institute of Psychiatry, King's College London, London, UK; Mario Amore, MD, PhD, Section of Psychiatry, Department of Neuroscience, Ophthalmology, Genetics and Infant-Maternal Science, University of Genoa, Italy; Marco Menchetti, MD, PhD, Department of Medical and Surgical Sciences, University of Bologna; Giulio Toni, MD, Cardiology Unit, Ramazzini Hospital, Carpi; Francesca Neviani, MD, PhD, Department of Geriatrics, Nuovo Ospedale Civile S. Agostino Estense, Modena and Reggio Emilia University, Modena; Matteo Cerri, MD, PhD, Department of Biomedical and Neuromotor Sciences, University of Bologna; Marco B. L. Rocchi, Department of Biomolecular Sciences, Service of Biostatistics, University of Urbino; Donato Zocchi, MD, Luigi Bagnoli, MD, primary care physicians, Bologna; Enrico Tam, PhD, Department of Movement and Neurological Sciences, University of Verona; Angela Buffa, MD, PhD, Unit of Internal Medicine, Geriatrics and Nephrology, S. Orsola Malpighi Hospital, Bologna; Serena Ferrara, PsyD, Consultation Liaison Psychiatry Service, Department of Mental Health, Bologna; Mirco Neri, Department of Geriatrics, Nuovo Ospedale Civile S. Agostino Estense, Modena and Reggio Emilia University, Modena, Italy; George S. Alexopoulos, MD, PhD, Department of Psychiatry, Weill Cornell Medical College, New York, USA; Stamatula Zanetidou, MD, Consultation Liaison Psychiatry Service, Department of Mental Health, Bologna, Italy; the Safety and Efficacy of Exercise for Depression in Seniors (SEEDS) Study Group martino.belvederi@gmail.com.

BACKGROUND Interventions including physical exercise may help improve the outcomes of late-life major depression, but few studies are available. OBJECTIVE To investigate whether augmenting sertraline therapy with physical exercise leads to better outcomes of late-life major depression. METHODS Primary care patients (465 years) with major depression were randomised to 24 weeks of higher-intensity, progressive aerobic exercise plus sertraline (S+PAE), lower-intensity, non-progressive exercise plus sertraline (S+NPE) and sertraline alone. The primary outcome was remission (a score of ≤10 on the Hamilton Rating Scale for Depression). RESULTS A total of 121 patients were included. At study end, 45% of participants in the sertraline group, 73% of those in the S+NPE group and 81% of those in the S+PAE group achieved remission (P = 0.001). A shorter time to remission was observed in the S+PAE group than in the sertraline-only group. CONCLUSIONS Physical exercise may be a safe and effective augmentation to antidepressant therapy in late-life major depression.

UI MeSH Term Description Entries
D008297 Male Males
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003865 Depressive Disorder, Major Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5) Depression, Involutional,Major Depressive Disorder,Melancholia, Involutional,Paraphrenia, Involutional,Psychosis, Involutional,Depressive Disorders, Major,Involutional Depression,Involutional Melancholia,Involutional Paraphrenia,Involutional Paraphrenias,Involutional Psychoses,Involutional Psychosis,Major Depressive Disorders,Paraphrenias, Involutional,Psychoses, Involutional
D005081 Exercise Therapy A regimen or plan of physical activities designed and prescribed for specific therapeutic goals. Its purpose is to restore normal musculoskeletal function or to reduce pain caused by diseases or injuries. Rehabilitation Exercise,Remedial Exercise,Therapy, Exercise,Exercise Therapies,Exercise, Rehabilitation,Exercise, Remedial,Exercises, Rehabilitation,Exercises, Remedial,Rehabilitation Exercises,Remedial Exercises,Therapies, Exercise
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000928 Antidepressive Agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems. Antidepressant,Antidepressant Drug,Antidepressant Medication,Antidepressants,Antidepressive Agent,Thymoanaleptic,Thymoanaleptics,Thymoleptic,Thymoleptics,Antidepressant Drugs,Agent, Antidepressive,Drug, Antidepressant,Medication, Antidepressant

Related Publications

M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
July 2013, Lancet (London, England),
M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
January 2020, The Journal of clinical psychiatry,
M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
March 2022, Translational psychiatry,
M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
February 2023, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists,
M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
December 2015, Lancet (London, England),
M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
December 2002, The Journal of clinical psychiatry,
M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
June 2010, The Journal of clinical psychiatry,
M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
June 2018, L'Encephale,
M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
January 2011, The Journal of clinical psychiatry,
M Belvederi Murri, and M Amore, and M Menchetti, and G Toni, and F Neviani, and M Cerri, and M B L Rocchi, and D Zocchi, and L Bagnoli, and E Tam, and A Buffa, and S Ferrara, and M Neri, and G S Alexopoulos, and S Zanetidou, and
March 2014, Psychiatric annals,
Copied contents to your clipboard!